RecruitingPHASE1, PHASE2NCT07061938

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Studying IgG4-related disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Acepodia Biotech, Inc.
Intervention
ACE1831(drug)
Enrollment
30 enrolled
Eligibility
18-75 years · All sexes
Timeline
2026 – 2027

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07061938 on ClinicalTrials.gov

Other trials for IgG4-related disease

Additional recruiting or active studies for the same condition.

See all trials for IgG4-related disease →

← Back to all trials